1099: Apremilast, an oral phosphodiesterase 4 inhibitor...

You must login or register to view this form.

Submitted by Anna Moll on Mon, 06/22/2015 - 3:28pm

Not started
CE/CME Statement
Open/Close details
- Required
Not started
1099: Apremilast, an oral phosphodiesterase 4 inhibitor...
Open/Close details
- Optional
Not started
1731: Secukinumab demonstrates sustained efficacy...
Open/Close details
- Optional
Not started
956: Maintenance of clinical response with long-term brodalumab (AMG 827) therapy...
Open/Close details
- Optional
Not started
2020: Two phase 3 studies of oral tofacitinib...
Open/Close details
- Optional
Not started
1670: A novel aerosol foam formulation of calcipotriene...
Open/Close details
- Optional
Not started
733: Cardiovascular risk factors in patients with moderate to severe psoriasis...
Open/Close details
- Optional
Not started
1744: Health care resource utilization, health care costs, and dose escalation...
Open/Close details
- Optional
Not started
1717: A practical model for early identification of response...
Open/Close details
- Optional
Not started
1956: Major adverse cardiovascular events in the PSOLAR...
Open/Close details
- Optional
Not started
1662: Features and dynamics of obesity in psoriasis...
Open/Close details
- Optional
Not started
Evaluation
Open/Close details
- Required
Not started
Credit
Open/Close details
- Optional
Not started
Certificate
Open/Close details
- Optional

Expand / Minimize

Annenberg Center